Erratum: METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours

Ecancermedicalscience. 2022 Jul 4:16:1421. doi: 10.3332/ecancer.2022.1421. eCollection 2022.

¹ Department of Clinical Oncology, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo - FMUSP, São Paulo, Brazil.
² Post Graduate Program, Faculdade de Medicina da Universidade de São Paulo, Brazil.
³ Department of Medical Radiology, Fleury Group, São Paulo, Brazil.
⁴ Department of Medical Radiology, Hospital Israelita Albert Einstein, São Paulo, Brazil.
⁵ Center for Translational Research in Oncology, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo - FMUSP, São Paulo, Brazil.
⁶ Department of Clinical Oncology, AC Camargo Cancer Center, São Paulo, Brazil.

Abstract

[This corrects the article on p. 1 in vol. 16.].

Keywords: cancer treatment; metformin; neuroendocrine tumours.